Compare Adaptive Biotechnologies Corp (ADPT) vs Atmos Energy Corporation (ATO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Atmos Energy Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Atmos Energy Corporation trades at $177.38 (market cap $29.64B). The key difference: Atmos Energy Corporation is far larger — about 8.9× Adaptive Biotechnologies Corp's market cap, and Atmos Energy Corporation pays a 2.25% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ATO | |
|---|---|---|
Market Cap | $3.33B | $29.64B |
Sector | Health | Utilities |
52-Week High | $22.37 | $192.25 |
52-Week Low | $10.24 | $151.99 |
Enterprise Value | $3.19B | $39.15B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ATO trades at $177.58, up 0.4% today, with a bearish technical signal but neutral oscillators. Recent earnings beat expectations in Q1 2026, with revenue growth to $4.7B in 2025 and a net margin of 27.58%. The stock shows strong profitability and a P/E of 21.41, while analyst consensus is a Buy with a $188.86 target. A dividend of $1.00 was recently declared, supporting income appeal.
Outlook is positive due to earnings beats and defensive utility positioning, but risks include high capital expenditures and debt levels. Investment opportunity lies in steady growth and dividend consistency, though market volatility and interest rate sensitivity pose challenges for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →
